)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Roquefort Therapeutics (ROQ) investor relations material
Roquefort Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary30 Sep, 2025
Executive summary
Announced strategic pivot from pre-clinical to clinical stage assets, highlighted by the proposed acquisition of Coiled Therapeutics, Inc., a clinical-stage oncology company with a promising Phase I asset (AO-252).
Signed binding agreements to sell Lyramid Pty Ltd for $10.8 million and Oncogeni Ltd for up to $12 million, with the Lyramid transaction expected to close by 31 October 2025.
Leadership changes included the resignation of the CEO and a Non-Executive Director, with Dr. Darrin Disley appointed as Interim Managing Director.
Financial highlights
Net loss for the six months ended 30 June 2025 was £467,167, an improvement from a £591,695 loss in the prior year period.
Cash at period end was £182,923, down from £595,662 at 30 June 2024.
Raised £236,000 via private placement to support working capital.
Basic and diluted loss per share was (0.33)p, compared to (0.45)p in the prior year period.
Outlook and guidance
Focused on completing the acquisition of Coiled Therapeutics and advancing AO-252 and STAT-6 programs into clinical trials.
Early Phase I data for AO-252 is encouraging, with plans for dose expansion in Q4 2025 and Phase III trial planning in 2026.
Company to be renamed Coiled Therapeutics plc and seek AIM Market admission upon transaction completion.
Explain Lyramid sale shareholder benefit plan.
Detail A2A Pharmaceuticals' £6M funding structure.
What is the rationale for moving to AIM Market?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Roquefort Therapeutics earnings date
H2 202528 Apr, 2026
Next Roquefort Therapeutics earnings date
H2 202528 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Roquefort Therapeutics PLC is a United Kingdom-based biotechnology company focused on developing novel therapies targeting cancer and autoimmune diseases. The company specializes in discovering and advancing small molecule and RNA-based therapeutics through its proprietary platforms. Its operations span early-stage research, preclinical testing, and strategic collaborations for drug development. Roquefort Therapeutics PLC is headquartered in London, United Kingdom, and its shares are listed on the LSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage